If the initial intent is to treat coronavirus, it will only be 4-8 doses per individual. You may have been calculating annual rates, but this is actually better as the revenue spike will be much faster given the large population in need of immediate treatment in this region (IF it proves effective and they ink a license agreement).

Given the target population NP and BP mentioned (hospitalized), does anyone know these figures for China (moderate to sever cases where hospitalized or in ICU)? That would provide an estimate quantity and I’m sure the price can be estimated based on general US and China prices for other drugs. Coronavirus treatment may even be higher than normal given the situation and lack of available treatments currently available.